Danbot: Strip excess bold

2026-03-22T09:28:45Z

Strip excess bold

Danbot: Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential template; bold retained for critical items only

2026-03-19T14:33:25Z

Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential template; bold retained for critical items only

Show changes

Ostermayer: /* See Also */

2026-03-11T15:35:15Z

Ostermayer at 15:34, 11 March 2026

2026-03-11T15:34:54Z

← Older revision		Revision as of 15:34, 11 March 2026
Line 1:		Line 1:
	Asbestosis is an irreversible, progressive interstitial pulmonary fibrosis caused by inhalation of asbestos fibers, characterized by '''basal-predominant fibrosis''' and typically accompanied by '''pleural plaques'''.<ref name="ATS2004">Diagnosis and initial management of nonmalignant diseases related to asbestos. ''Am J Respir Crit Care Med''. 2004;170(6):691-715.</ref> It clinically resembles [[idiopathic pulmonary fibrosis]] (IPF) but progresses more slowly. Asbestosis is one of several asbestos-related diseases, which also include benign pleural effusion, pleural plaques, diffuse pleural thickening, rounded atelectasis, '''[[lung cancer]]''', and '''[[mesothelioma]]'''.<ref name="AMBOSS">Asbestos-related diseases. ''AMBOSS''. Updated 2024.</ref> The latency period from first exposure to disease is typically '''>20 years'''.<ref name="AMBOSS"/> The '''most common malignancy''' associated with asbestos exposure is lung cancer, not mesothelioma.<ref name="AMBOSS"/> There is no cure — management is supportive. The ED physician's key roles are recognizing asbestos-related disease on imaging, evaluating acute complications, screening for malignancy, and ensuring appropriate occupational medicine referral.		Asbestosis is an irreversible, progressive interstitial pulmonary fibrosis caused by inhalation of asbestos fibers, characterized by '''basal-predominant fibrosis''' and typically accompanied by '''pleural plaques'''.<ref name="ATS2004">Diagnosis and initial management of nonmalignant diseases related to asbestos. ''Am J Respir Crit Care Med''. 2004;170(6):691-715.</ref> It clinically resembles [[idiopathic pulmonary fibrosis]] (IPF) but progresses more slowly. Asbestosis is one of several asbestos-related diseases, which also include benign pleural effusion, pleural plaques, diffuse pleural thickening, rounded atelectasis, '''lung cancer''', and '''mesothelioma'''.<ref name="AMBOSS">Asbestos-related diseases. ''AMBOSS''. Updated 2024.</ref> The latency period from first exposure to disease is typically '''>20 years'''.<ref name="AMBOSS"/> The '''most common malignancy''' associated with asbestos exposure is lung cancer, not mesothelioma.<ref name="AMBOSS"/> There is no cure — management is supportive. The ED physician's key roles are recognizing asbestos-related disease on imaging, evaluating acute complications, screening for malignancy, and ensuring appropriate occupational medicine referral.

	==Background==		==Background==
Line 177:		Line 177:
	*[[Pneumoconiosis]]		*[[Pneumoconiosis]]
	*[[Idiopathic pulmonary fibrosis]]		*[[Idiopathic pulmonary fibrosis]]
	*[[Lung cancer]]
	*[[Pleural effusion]]		*[[Pleural effusion]]
	*[[Heavy metal toxicity]]		*[[Heavy metal toxicity]]

Ostermayer: Created page with "Asbestosis is an irreversible, progressive interstitial pulmonary fibrosis caused by inhalation of asbestos fibers, characterized by '''basal-predominant fibrosis''' and typically accompanied by '''pleural plaques'''.Diagnosis and initial management of nonmalignant diseases related to asbestos. ''Am J Respir Crit Care Med''. 2004;170(6):691-715. It clinically resembles idiopathic pulmonary fibrosis (IPF) but progresses more slowly. Asbestosi..."

2026-03-11T15:34:16Z

Created page with "Asbestosis is an irreversible, progressive interstitial pulmonary fibrosis caused by inhalation of asbestos fibers, characterized by '''basal-predominant fibrosis''' and typically accompanied by '''pleural plaques'''.<ref name="ATS2004">Diagnosis and initial management of nonmalignant diseases related to asbestos. ''Am J Respir Crit Care Med''. 2004;170(6):691-715.</ref> It clinically resembles idiopathic pulmonary fibrosis (IPF) but progresses more slowly. Asbestosi..."

New page

Asbestosis is an irreversible, progressive interstitial pulmonary fibrosis caused by inhalation of asbestos fibers, characterized by '''basal-predominant fibrosis''' and typically accompanied by '''pleural plaques'''.<ref name="ATS2004">Diagnosis and initial management of nonmalignant diseases related to asbestos. ''Am J Respir Crit Care Med''. 2004;170(6):691-715.</ref> It clinically resembles [[idiopathic pulmonary fibrosis]] (IPF) but progresses more slowly. Asbestosis is one of several asbestos-related diseases, which also include benign pleural effusion, pleural plaques, diffuse pleural thickening, rounded atelectasis, '''[[lung cancer]]''', and '''[[mesothelioma]]'''.<ref name="AMBOSS">Asbestos-related diseases. ''AMBOSS''. Updated 2024.</ref> The latency period from first exposure to disease is typically '''>20 years'''.<ref name="AMBOSS"/> The '''most common malignancy''' associated with asbestos exposure is lung cancer, not mesothelioma.<ref name="AMBOSS"/> There is no cure — management is supportive. The ED physician's key roles are recognizing asbestos-related disease on imaging, evaluating acute complications, screening for malignancy, and ensuring appropriate occupational medicine referral.

==Background==
*Asbestos is a group of naturally occurring silicate mineral fibers historically used in insulation, fireproofing, roofing, brake linings, cement, shipbuilding, textiles, and gaskets<ref name="ATS2004"/>
*'''Two fiber types:'''
**'''Amphibole''' (amosite, crocidolite, tremolite) — straight, rigid needles; '''more fibrogenic and carcinogenic'''; most strongly linked to mesothelioma<ref name="MesoStatPearls">Malignant Mesothelioma. ''StatPearls''. NCBI Bookshelf. Updated January 2025.</ref>
**'''Serpentine''' (chrysotile) — curly fibers; accounts for >90% of asbestos used commercially worldwide; less fibrogenic but still carcinogenic<ref name="ATS2004"/>
*'''High-risk occupations:''' Shipyard workers, construction workers (especially demolition/renovation of older buildings), insulation installers/removers, plumbers, pipefitters, electricians, boilermakers, brake mechanics, roofers, naval personnel, miners, power plant workers<ref name="ATS2004"/>
*'''Passive/household exposure:''' Workers carrying asbestos fibers home on clothing → household contacts (especially mesothelioma risk); residential proximity to asbestos mines or processing plants<ref name="ATS2004"/>
*'''Latency:''' Typically '''20–40 years''' from first exposure to clinical disease; asbestos-related diseases may continue to present decades after exposure ceased<ref name="ATS2004"/>
*'''Pathogenesis:''' Inhaled asbestos fibers reach alveoli → phagocytosed by macrophages → fibers cannot be cleared → chronic inflammation → fibroblast activation → '''dose-dependent''' interstitial fibrosis (peribronchiolar and subpleural)<ref name="ATS2004"/>
*'''Asbestos bodies:''' Iron-coated asbestos fibers visible on light microscopy as golden-brown, dumbbell-shaped structures; marker of asbestos exposure but not disease<ref name="ATS2004"/>
*'''Smoking interaction:''' Smoking '''does not''' increase mesothelioma risk, but has a '''multiplicative effect''' on lung cancer risk in asbestos-exposed individuals (~50-fold combined risk vs. ~5-fold for asbestos alone and ~10-fold for smoking alone)<ref name="ATS2004"/>
*'''Spectrum of asbestos-related disease:'''
**'''Benign:''' Pleural plaques (most common manifestation of asbestos exposure), diffuse pleural thickening, benign asbestos-related pleural effusion (BAPE), rounded atelectasis, asbestosis
**'''Malignant:''' Lung cancer (most common malignancy), malignant [[mesothelioma]] (pleural > peritoneal > pericardial), laryngeal cancer, ovarian cancer<ref name="AMBOSS"/>
*US EPA moved toward a comprehensive ban on asbestos in 2024; asbestos is already banned in >60 countries worldwide<ref name="AMBOSS"/>

==Clinical Features==
*'''Insidious onset''' — symptoms typically appear '''20–30+ years''' after initial exposure<ref name="ATS2004"/>
*'''Progressive exertional dyspnea''' — the most common and often earliest symptom
*Persistent dry cough (may become productive with superimposed infection)
*Fatigue, reduced exercise tolerance
*Chest tightness or vague chest discomfort
*'''Physical exam:'''
**'''Bibasal end-inspiratory ("Velcro") crackles''' — the hallmark finding; identical to those in IPF<ref name="ATS2004"/>
**'''Digital clubbing''' — present in advanced disease (~40–50% of cases); more common than in most other pneumoconioses<ref name="ATS2004"/>
**Cyanosis in advanced disease
**Signs of right heart failure/[[cor pulmonale]] in end-stage disease (elevated JVP, peripheral edema, hepatomegaly)
*'''Pleural plaques''' are usually '''asymptomatic''' and are a marker of exposure, not disease severity — however, their presence strongly supports asbestos as the etiology of any concurrent fibrosis<ref name="ATS2004"/>
*'''Asbestos-related pleural effusion (BAPE):'''
**Usually occurs earlier than asbestosis (within 10–20 years of exposure)
**Typically small, unilateral, exudative, often hemorrhagic
**'''Diagnosis of exclusion''' — must rule out mesothelioma (requires thoracoscopy/biopsy in many cases)<ref name="ATS2004"/>
**May be recurrent; may resolve spontaneously
*'''Rounded atelectasis:''' Subpleural mass-like opacity with "comet tail" of bronchovascular structures; can mimic lung cancer on imaging; results from folding of thickened visceral pleura<ref name="ATS2004"/>

'''ED presentations:'''
*Progressive dyspnea in a patient with known or newly discovered asbestosis
*Acute respiratory infection superimposed on chronic fibrosis
*New pleural effusion requiring evaluation (BAPE vs. mesothelioma vs. infection vs. CHF)
*Incidental pleural plaques found on CXR or CT — triggers need for occupational history and referral
*Hemoptysis (raises concern for lung cancer or mesothelioma)
*Acute chest pain + effusion + weight loss → mesothelioma until proven otherwise
*Respiratory failure in end-stage disease

==Differential Diagnosis==
*[[Idiopathic pulmonary fibrosis]] (IPF) — '''the most important differential'''; both cause basal-predominant fibrosis with UIP pattern; differentiated by exposure history and presence of pleural plaques; asbestosis progresses more slowly than IPF<ref name="AMBOSS"/>
*Other pneumoconioses: [[Silicosis]] (upper-lobe predominant; round opacities; different exposure), [[beryllium toxicity|chronic beryllium disease]] (granulomatous; BeLPT positive)
*Connective tissue disease-associated ILD ([[rheumatoid arthritis]], [[scleroderma]])
*[[Hypersensitivity pneumonitis]] (fibrotic HP — exposure history differs; often upper/mid zone; air trapping; rare pleural involvement)
*Drug-induced pulmonary fibrosis ([[amiodarone]], [[methotrexate]], [[bleomycin]], [[nitrofurantoin]])
*[[Sarcoidosis]] (upper-zone predominant; hilar lymphadenopathy; non-caseating granulomas)
*Radiation fibrosis
*'''For pleural disease:'''
**[[Mesothelioma]] (nodular pleural thickening; circumferential; effusion; weight loss)
**Metastatic pleural disease
**[[Tuberculosis]] (pleural effusion, especially in endemic areas)
**[[CHF]] (bilateral effusions; cardiomegaly)

==Evaluation==
===Workup===
'''History — essential:'''
*'''Detailed lifetime occupational history:''' All jobs held; specifically ask about shipyards, construction, demolition, renovation of pre-1980s buildings, insulation work, plumbing, brake repair, roofing, mining, power plants, naval service
*'''Household/environmental exposure:''' Lived with asbestos worker; proximity to asbestos processing; older home with deteriorating insulation
*Latency from first exposure (usually >20 years)
*Smoking history (critical for lung cancer risk stratification — multiplicative interaction)
*Prior asbestos-related disease (pleural plaques, prior effusions)
*Symptoms suggesting malignancy: weight loss, night sweats, new chest wall pain, hemoptysis, rapidly increasing effusion

'''Laboratory (ED):'''
*CBC, CMP
*ABG/VBG: Hypoxemia (exercise-induced desaturation is early finding)
*BNP/NT-proBNP if right heart failure suspected
*If pleural effusion tapped: cell count, LDH, protein, glucose, pH, cytology, triglycerides (rule out chylothorax from lymphatic obstruction by mesothelioma)
*No specific serum biomarker for asbestosis
*Mesothelin (SMRP): A serum biomarker under investigation for mesothelioma screening — not yet standard of care and not an ED test<ref name="MesoStatPearls"/>

'''Imaging:'''

''Chest X-ray:''
*'''Normal in 10–20%''' of patients with histologically confirmed asbestosis<ref name="ATS2004"/>
*'''Bilateral, basal-predominant reticulonodular opacities''' — the classic finding
*'''Pleural plaques:''' Discrete areas of pleural thickening, often calcified, typically bilateral, along posterolateral chest wall (ribs 7–10), diaphragm, and mediastinal pleura; '''apices and costophrenic angles are typically spared'''<ref name="Medscape">Asbestosis Imaging. ''Medscape/eMedicine''. Updated 2024.</ref>
*'''"Shaggy" cardiac silhouette and diaphragmatic contours''' — from basal fibrosis obscuring smooth borders<ref name="RadioGraphics">Asbestos: when the dust settles — an imaging review of asbestos-related disease. ''RadioGraphics''. 2002;22(suppl):S167-S184.</ref>
*Diffuse pleural thickening (continuous sheet, may obliterate costophrenic angles — unlike focal plaques)
*Rounded atelectasis: Subpleural rounded opacity with "comet tail" sign
*Pleural effusion (unilateral or bilateral)
*CXR sensitivity for pleural plaques: only 50–80% compared to CT<ref name="ATS2004"/>

''HRCT — the key imaging modality:''
*'''Subpleural "dotlike" opacities''' and subpleural curvilinear lines — earliest HRCT findings of asbestosis; represent peribronchiolar fibrosis<ref name="Medscape"/>
*Intralobular and interlobular septal thickening ('''basal-predominant''')
*Parenchymal bands (linear opacities 2–5 cm extending from pleura into lung)
*Honeycombing in advanced disease (identical to UIP/IPF pattern)
*'''Pleural plaques''' — HRCT is far more sensitive than CXR; presence alongside basal fibrosis is virtually diagnostic of asbestosis in the appropriate clinical context<ref name="ATS2004"/>
*'''Prone images are essential''' — distinguish true subpleural fibrosis from dependent atelectasis (gravity-related opacity in supine position)<ref name="Medscape"/>
*'''Key distinction from IPF:''' Subpleural dotlike opacities, parenchymal bands, and mosaic perfusion are '''more common''' in asbestosis; visible intralobular bronchioles and honeycombing are '''more prominent''' in IPF<ref name="AJR">Akira M, et al. High-resolution CT of asbestosis and idiopathic pulmonary fibrosis. ''AJR Am J Roentgenol''. 2003;181(1):163-169.</ref>
*'''Rounded atelectasis:''' Round/oval mass abutting thickened pleura with "comet tail" of curving bronchovascular bundles entering the mass — do NOT mistake for lung cancer (CT appearance is usually diagnostic; PET may be falsely positive)<ref name="ATS2004"/>

'''PFTs''' (outpatient):
*'''Restrictive''' pattern: Reduced FVC, reduced TLC<ref name="ATS2004"/>
*'''Reduced DLCO''' — often the earliest functional abnormality; correlates with extent of fibrosis
*Exercise-induced desaturation (useful for detecting early disease)
*Obstructive component may be present (airway involvement, concurrent COPD from smoking)

===Diagnosis===
*'''Clinical-radiographic diagnosis''' based on:<ref name="ATS2004"/>
**(1) '''Reliable history of asbestos exposure''' with appropriate latency (typically >20 years)
**(2) '''Imaging consistent with asbestosis''' (basal-predominant fibrosis on CXR or HRCT)
**(3) '''Exclusion of other causes''' of pulmonary fibrosis
*Presence of '''pleural plaques''' alongside basal fibrosis greatly increases diagnostic confidence — plaques are a reliable marker of asbestos exposure<ref name="ATS2004"/>
*'''Lung biopsy is rarely required''' — clinical-radiographic diagnosis is sufficient in most cases; biopsy only when diagnosis is uncertain and management would change<ref name="ATS2004"/>
*If biopsied: Peribronchiolar and subpleural fibrosis with '''asbestos bodies''' (golden-brown, dumbbell-shaped, iron-coated fibers) on light microscopy<ref name="ATS2004"/>
*'''In the ED:''' Consider asbestosis when you see bilateral basal fibrosis + pleural plaques on imaging — obtain occupational history and ensure pulmonology/occupational medicine referral

==Management==
'''There is no cure for asbestosis and no specific treatment — management is entirely supportive'''<ref name="Merck">Asbestosis. ''Merck Manual Professional Edition''. Updated April 2025.</ref>

'''1. Remove from further asbestos exposure''' — though disease typically diagnosed long after exposure has ceased

'''2. ED management of acute presentations:'''
*Supplemental O2 to maintain SpO2 ≥90%
*Bronchodilators for patients with reversible airway component
*Treat superimposed respiratory infections with appropriate antibiotics
*Non-invasive ventilation or intubation for respiratory failure
*Treat right heart failure/[[cor pulmonale]] (diuretics, O2)
*Thoracentesis for symptomatic pleural effusion — '''always send cytology''' to evaluate for mesothelioma; hemorrhagic exudative effusion in an asbestos-exposed patient requires thoracoscopy/biopsy if cytology is negative<ref name="ATS2004"/>

'''3. Malignancy surveillance — critical responsibility:'''
*'''Lung cancer:''' The most common asbestos-related malignancy; risk is multiplicative with smoking (~50× for combined exposure); consider low-dose CT screening per USPSTF guidelines in appropriate patients; '''smoking cessation is the single most impactful intervention for reducing lung cancer risk''' in asbestos-exposed individuals
*'''Mesothelioma:''' Latency 25–70 years (median 30–40 years) after first exposure; insidious onset with dyspnea, chest wall pain, and pleural effusion (present in ~90%); median survival 12–21 months; treatment: nivolumab + ipilimumab (FDA-approved for unresectable mesothelioma), surgery (pleurectomy/decortication or extrapleural pneumonectomy in selected patients), chemotherapy (cisplatin + pemetrexed), radiation<ref name="MesoStatPearls"/>
*'''Any new pleural effusion, pleural thickening, or chest wall pain in a patient with asbestos exposure history warrants aggressive evaluation for mesothelioma'''

'''4. Long-term management (coordinate with pulmonology/occupational medicine):'''
*Smoking cessation ('''mandatory''' — reduces lung cancer risk)
*Pulmonary rehabilitation
*Supplemental O2 for chronic hypoxemia
*Annual influenza vaccination; pneumococcal vaccination; COVID-19 vaccination
*Serial PFTs to monitor progression
*Low-dose CT lung cancer screening (per USPSTF criteria)
*Lung transplantation for end-stage fibrosis (rare; most patients are elderly with comorbidities)
*No proven antifibrotic therapy for asbestosis specifically (nintedanib/pirfenidone have not been specifically studied)

'''5. Reporting and compensation:'''
*Document exposure history thoroughly — asbestosis is a compensable occupational disease
*Report to occupational health/public health authorities as required
*Patients may be eligible for workers' compensation, asbestos trust fund compensation, or legal claims
*Workplace contacts may need evaluation (household contacts at risk for mesothelioma from passive exposure)

==Disposition==
*'''Admit:'''
**Respiratory failure or significant new hypoxemia
**New pleural effusion requiring evaluation (especially if concern for mesothelioma — expedite thoracoscopy/biopsy)
**Hemoptysis requiring evaluation (lung cancer vs. infection)
**Severe respiratory infection superimposed on chronic fibrosis
**Cor pulmonale/right heart failure
*'''Discharge with close follow-up:'''
**Stable known asbestosis with symptoms at baseline
**Incidental finding of pleural plaques in an asymptomatic patient — arrange occupational medicine/pulmonology referral for baseline PFTs and HRCT
**New suspected asbestosis in stable patient — arrange:
***Pulmonology and/or occupational medicine referral within 1–2 weeks
***HRCT with prone images if not performed
***PFTs with DLCO
***Low-dose CT lung cancer screening discussion
*'''Discharge counseling:'''
**Return for worsening dyspnea, hemoptysis, new chest pain, or fever
**'''Smoking cessation''' (most important modifiable risk factor for lung cancer)
**Avoid further asbestos exposure (especially during home renovation of older buildings)
**All household contacts of asbestos workers should be informed of mesothelioma risk
**Report exposure to occupational health for workplace evaluation

==See Also==
*[[Mesothelioma]]
*[[Silicosis]]
*[[Beryllium toxicity]]
*[[Pneumoconiosis]]
*[[Idiopathic pulmonary fibrosis]]
*[[Lung cancer]]
*[[Pleural effusion]]
*[[Heavy metal toxicity]]

==External Links==
*[https://www.atsjournals.org/doi/10.1164/rccm.200310-1436ST ATS Statement: Diagnosis and Initial Management of Nonmalignant Asbestos-Related Diseases (2004)]
*[https://www.merckmanuals.com/professional/pulmonary-disorders/environmental-and-occupational-pulmonary-diseases/asbestosis Asbestosis — Merck Manual Professional]
*[https://emedicine.medscape.com/article/295966-overview Asbestosis — Medscape]
*[https://emedicine.medscape.com/article/352900-overview Asbestosis Imaging — Medscape]
*[https://www.osha.gov/asbestos Asbestos — OSHA]
*[https://www.cdc.gov/niosh/topics/asbestos/ Asbestos — NIOSH/CDC]

==References==
<references/>

[[Category:Pulmonary]]
[[Category:Toxicology]]

← Older revision		Revision as of 15:35, 11 March 2026
Line 172:		Line 172:

	==See Also==		==See Also==
	*[[Mesothelioma]]
	*[[Silicosis]]		*[[Silicosis]]
	*[[Beryllium toxicity]]		*[[Beryllium toxicity]]

Asbestosis - Revision history

Danbot: Strip excess bold

Danbot: Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential template; bold retained for critical items only

Ostermayer: /* See Also */

Ostermayer at 15:34, 11 March 2026